LEO LUZNIK to Hematologic Neoplasms
This is a "connection" page, showing publications LEO LUZNIK has written about Hematologic Neoplasms.
Connection Strength
3.366
-
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
Score: 0.385
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
Score: 0.357
-
Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019 05 06; 129(6):2189-2191.
Score: 0.299
-
Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
Score: 0.255
-
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016 Jan; 13(1):10-24.
Score: 0.231
-
Are alternative donors really still "alternative?". Biol Blood Marrow Transplant. 2014 Oct; 20(10):1463-4.
Score: 0.215
-
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22; 115(16):3224-30.
Score: 0.157
-
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun; 14(6):641-50.
Score: 0.140
-
Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002 Mar-Apr; 9(2):123-37.
Score: 0.091
-
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020 08 25; 4(16):3913-3925.
Score: 0.082
-
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV. 2020 09; 7(9):e602-e610.
Score: 0.081
-
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
Score: 0.077
-
Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2431-2437.
Score: 0.076
-
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biol Blood Marrow Transplant. 2018 10; 24(10):2056-2064.
Score: 0.070
-
Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 04; 24(4):666-677.
Score: 0.068
-
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018 02; 24(2):343-352.
Score: 0.067
-
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
Score: 0.063
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016 Apr 12; 9:35.
Score: 0.060
-
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016 Apr; 53(2):90-7.
Score: 0.059
-
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
Score: 0.059
-
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
Score: 0.058
-
Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan; 22(1):112-8.
Score: 0.058
-
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
Score: 0.058
-
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
Score: 0.056
-
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016 Jan; 96(1):27-35.
Score: 0.056
-
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
Score: 0.053
-
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul; 47(1-3):65-77.
Score: 0.040
-
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
Score: 0.039
-
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr; 12(4):414-21.
Score: 0.030
-
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1099-1102.
Score: 0.017
-
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
Score: 0.006